PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

NCT05659186 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Tislelizumab
DRUG: Anlotinib
RADIATION: Radiotherapy

Sponsor

West China Hospital